{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T03:33:41Z","timestamp":1784000021095,"version":"3.55.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009827","name":"Laura and John Arnold Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009827","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014848","name":"Arnold Ventures","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014848","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008510","name":"The University of Maryland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008510","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jclinepi.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Epidemiology"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.jclinepi.2023.10.014","type":"journal-article","created":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T19:19:17Z","timestamp":1697915957000},"page":"76-87","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Harms were detected but not reported in six clinical trials of gabapentin"],"prefix":"10.1016","volume":"164","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6126-2459","authenticated-orcid":false,"given":"Evan","family":"Mayo-Wilson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6670-4874","authenticated-orcid":false,"given":"Riaz","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwanhee","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianjing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jclinepi.2023.10.014_bib1","author":"Dickersin"},{"key":"10.1016\/j.jclinepi.2023.10.014_bib2","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/1745-6215-13-136","article-title":"Implementation of a publication strategy in the context of reporting biases. A case study based on new documents from Neurontin litigation","volume":"13","author":"Vedula","year":"2012","journal-title":"Trials"},{"key":"10.1016\/j.jclinepi.2023.10.014_bib3","doi-asserted-by":"crossref","first-page":"284","DOI":"10.7326\/0003-4819-145-4-200608150-00008","article-title":"Narrative review: the promotion of gabapentin: an analysis of internal industry documents","volume":"145","author":"Steinman","year":"2006","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.jclinepi.2023.10.014_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001378","article-title":"Differences in reporting of analyses in internal company documents versus published trial reports: comparisons in industry-sponsored trials in off-label uses of gabapentin","volume":"10","author":"Vedula","year":"2013","journal-title":"PLoS Med"},{"key":"10.1016\/j.jclinepi.2023.10.014_bib5","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMsa0906126","article-title":"Outcome reporting in industry-sponsored trials of gabapentin for off-label use","volume":"361","author":"Vedula","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jclinepi.2023.10.014_bib6","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jclinepi.2017.07.014","article-title":"Cherry-picking by trialists and meta-analysts can drive conclusions about intervention efficacy","volume":"91","author":"Mayo-Wilson","year":"2017","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jclinepi.2023.10.014_bib7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jclinepi.2019.04.022","article-title":"Harms are assessed inconsistently and reported inadequately part 1: systematic adverse events","volume":"113","author":"Mayo-Wilson","year":"2019","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jclinepi.2023.10.014_bib8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jclinepi.2019.04.020","article-title":"Harms are assessed inconsistently and reported inadequately part 2: nonsystematic adverse events","volume":"113","author":"Mayo-Wilson","year":"2019","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.jclinepi.2023.10.014_bib9","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1186\/s13063-019-3581-3","article-title":"Opportunities for selective reporting of harms in randomized clinical trials: selection criteria for non-systematic adverse events","volume":"20","author":"Mayo-Wilson","year":"2019","journal-title":"Trials"},{"key":"10.1016\/j.jclinepi.2023.10.014_bib10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jclinepi.2017.05.007","article-title":"Multiple outcomes and analyses in clinical trials create challenges for interpretation and research synthesis","volume":"86","author":"Mayo-Wilson","year":"2017","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"10.1016\/j.jclinepi.2023.10.014_bib11","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1056\/NEJMp0808659","article-title":"The Neurontin legacy--marketing through misinformation and manipulation","volume":"360","author":"Landefeld","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jclinepi.2023.10.014_bib12","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1136\/bmj.328.7450.1217","article-title":"Pfizer pleads guilty, but drug sales continue to soar","volume":"328","author":"Lenzer","year":"2004","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.jclinepi.2023.10.014_bib13","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1001\/jamainternmed.2017.7856","article-title":"Gabapentinoid use in the United States 2002 through 2015","volume":"178","author":"Johansen","year":"2018","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jclinepi.2023.10.014_bib14","series-title":"The top 300 of 2020. ClinCalc DrugStats database version 2022.08: prescription data source: medical expenditure panel survey (MEPS) 2013-2020","author":"DrugStats","year":"2022"},{"key":"10.1016\/j.jclinepi.2023.10.014_bib15","series-title":"OpenPrescribing.net","year":"2022"},{"issue":"5","key":"10.1016\/j.jclinepi.2023.10.014_bib16","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMp1704633","article-title":"Gabapentin and pregabalin for pain \u2014 is increased prescribing a cause for concern?","volume":"377","author":"Goodman","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jclinepi.2023.10.014_bib17","article-title":"Gabapentin for chronic neuropathic pain in adults","volume":"6","author":"Wiffen","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jclinepi.2023.10.014_bib18","series-title":"Cochrane Database of Systematic Reviews; 2019","article-title":"Published research overestimates effectiveness and underestimates harms of gabapentin (comment on Gabapentin for chronic neuropathic pain in adults)","author":"Mayo-Wilson","year":"2019"},{"key":"10.1016\/j.jclinepi.2023.10.014_bib19","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1001\/jama.2017.21547","article-title":"Gabapentin for chronic neuropathic pain","volume":"319","author":"Moore","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.jclinepi.2023.10.014_bib20","doi-asserted-by":"crossref","first-page":"m1315","DOI":"10.1136\/bmj.m1315","article-title":"Pregabalin and gabapentin for pain","volume":"369","author":"Mathieson","year":"2020","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.jclinepi.2023.10.014_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-002496","article-title":"Clinical study reports of randomised controlled trials: an exploratory review of previously confidential industry reports","volume":"3","author":"Doshi","year":"2013","journal-title":"BMJ Open"},{"issue":"6","key":"10.1016\/j.jclinepi.2023.10.014_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-047785","article-title":"Restoring invisible and abandoned trials of gabapentin for neuropathic pain: a clinical and methodological investigation","volume":"11","author":"Mayo-Wilson","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.jclinepi.2023.10.014_bib23","series-title":"Protocol Number: 945-210","article-title":"Research report: 720-03908. A double-blind placebo-controlled trial of gabapentin for treatment of painful diabetic peripheral neuropathy","year":"1998"},{"key":"10.1016\/j.jclinepi.2023.10.014_bib27","series-title":"Protocol Number: 945-430-306 (NN 026)","article-title":"Research report: RR 430-00125. A double blind placebo controlled trial of gabapentin for the treatment of patients exhibiting symptoms of neuropathic pain","year":"2000"},{"key":"10.1016\/j.jclinepi.2023.10.014_bib28","series-title":"Protocol A945-A1008","article-title":"Final study report: a 15 Week randomized, double-blind, placebo controlled, parallel-group, multicenter study of Neurontin (gabapentin) for eficacy and quality of life in patients with painful diabetic peripheral neuropahty","year":"2005"},{"key":"10.1016\/j.jclinepi.2023.10.014_bib29","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13643-015-0134-z","article-title":"Integrating multiple data sources (MUDS) for meta-analysis to improve patient-centered outcomes research: a protocol","volume":"4","author":"Mayo-Wilson","year":"2015","journal-title":"Syst Rev"},{"key":"10.1016\/j.jclinepi.2023.10.014_bib30","doi-asserted-by":"crossref","first-page":"f2865","DOI":"10.1136\/bmj.f2865","article-title":"Restoring invisible and abandoned trials: a call for people to publish the findings","volume":"346","author":"Doshi","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.jclinepi.2023.10.014_bib31","doi-asserted-by":"crossref","first-page":"k1742","DOI":"10.1136\/bmj.k1742","article-title":"Restoring biomedical literature with RIAT","volume":"361","author":"Doshi","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.jclinepi.2023.10.014_bib32","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1001\/jama.280.21.1831","article-title":"Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial","volume":"280","author":"Backonja","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.jclinepi.2023.10.014_bib33","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1001\/jama.280.21.1837","article-title":"Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial","volume":"280","author":"Rowbotham","year":"1998","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.jclinepi.2023.10.014_bib34","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0304-3959(01)00407-9","article-title":"Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study","volume":"94","author":"Rice","year":"2001","journal-title":"Pain"},{"issue":"3","key":"10.1016\/j.jclinepi.2023.10.014_bib35","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0304-3959(02)00255-5","article-title":"Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial","volume":"99","author":"Serpell","year":"2002","journal-title":"Pain"},{"key":"10.1016\/j.jclinepi.2023.10.014_bib36","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/epirev\/mxac005","article-title":"Comparing the value of data visualization methods for communicating harms in clinical trials","volume":"44","author":"Qureshi","year":"2022","journal-title":"Epidemiol Rev"},{"key":"10.1016\/j.jclinepi.2023.10.014_bib37","series-title":"Dryad","article-title":"Data from: Cherry-picking by trialists and meta-analysts can drive conclusions about intervention efficacy","author":"Mayo-Wilson","year":"2018"},{"key":"10.1016\/j.jclinepi.2023.10.014_bib38","series-title":"Coding symbols for a thesaurus of adverse reaction terms 5th ed","year":"1995"},{"key":"10.1016\/j.jclinepi.2023.10.014_bib40","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf"},{"key":"10.1016\/j.jclinepi.2023.10.014_bib52","series-title":"Handbook of Transnational Economic Governance Regimes: Brill | Nijhoff, Leiden, Netherlands","article-title":"International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use","author":"Abraham","year":"2010"},{"key":"10.1016\/j.jclinepi.2023.10.014_bib54","series-title":"Guideline on good pharmacovigilance practices (GVP): ANNEX I - Definitions (Rev 4)","year":"2017"},{"key":"10.1016\/j.jclinepi.2023.10.014_bib41","author":"Mayo-Wilson"},{"key":"10.1016\/j.jclinepi.2023.10.014_bib43","article-title":"CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomised trials","volume":"381","author":"Junqueira","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.jclinepi.2023.10.014_bib44","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1740774520969136","article-title":"Meta-analysis of rare adverse events in randomized clinical trials: Bayesian and frequentist methods","volume":"18","author":"Hong","year":"2021","journal-title":"Clin Trials"},{"key":"10.1016\/j.jclinepi.2023.10.014_bib45","series-title":"R: A language and environment for statistical computing [program]","year":"2016"},{"key":"10.1016\/j.jclinepi.2023.10.014_bib46","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jclinepi.2021.10.024","article-title":"Harms in systematic reviews paper 2: methods used to assess harms are neglected in systematic reviews of gabapentin","volume":"143","author":"Qureshi","year":"2022","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jclinepi.2023.10.014_bib47","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jclinepi.2021.10.025","article-title":"Harms in systematic reviews paper 3: given the same data sources, systematic reviews of gabapentin have different results for harms","volume":"143","author":"Qureshi","year":"2022","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"10.1016\/j.jclinepi.2023.10.014_bib48","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-024537","article-title":"Analysis and reporting of adverse events in randomised controlled trials: a review","volume":"9","author":"Phillips","year":"2019","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.jclinepi.2023.10.014_bib49","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13643-023-02234-0","article-title":"Conducting separate reviews of benefits and harms could improve systematic reviews and meta-analyses","volume":"12","author":"Mayo-Wilson","year":"2023","journal-title":"Syst Rev"},{"key":"10.1016\/j.jclinepi.2023.10.014_bib50","series-title":"FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin (Neurontin, Gralise, Horizant) and pregabalin (Lyrica, Lyrica CR) when used with CNS depressants or in patients with lung problems","year":"2019"},{"key":"10.1016\/j.jclinepi.2023.10.014_bib51","article-title":"Creanor S, et al. Visualising harms in publications of randomised controlled trials: consensus and recommendations","volume":"377","author":"Phillips","year":"2022","journal-title":"BMJ"}],"container-title":["Journal of Clinical Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0895435623002743?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0895435623002743?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T05:26:00Z","timestamp":1760246760000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0895435623002743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":48,"alternative-id":["S0895435623002743"],"URL":"https:\/\/doi.org\/10.1016\/j.jclinepi.2023.10.014","relation":{"has-preprint":[{"id-type":"doi","id":"10.31222\/osf.io\/ej7fp","asserted-by":"object"}]},"ISSN":["0895-4356"],"issn-type":[{"value":"0895-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Harms were detected but not reported in six clinical trials of gabapentin","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Epidemiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jclinepi.2023.10.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}